Cardurion Pharmaceuticals Appoints Ron Renaud to Board of Directors

Veteran biotech industry leader joins as company enters next stage of growth BURLINGTON, Mass. – September 26, 2024 –Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Ron Renaud as a member of the company’s Board of Directors.